Preclinical Safety Profile of an Oral Naringenin/Hesperidin Dosage Form by In Vivo Toxicological Tests

Preclinical Safety Profile of an Oral Naringenin/Hesperidin Dosage Form by In Vivo Toxicological Tests

We developed a naringenin–hesperidin molar mixture (MIX–160) with proven antihyperglycemic and vasorelaxant activity in preclinical studies. A solid dosage form was manufactured to improve the bioavailability properties. In the current study, we sought to evaluate the oral preclinical toxicity of th...

Full description

Bibliographic Details
Main Authors: Carla Georgina Cicero-Sarmiento, Rolffy Ortiz-Andrade, Jesús Alfredo Araujo-León, Maira Rubí Segura-Campos, Priscila Vazquez-Garcia, Héctor Rubio-Zapata, Efrén Hernández-Baltazar, Victor Yañez-Pérez, Amanda Sánchez-Recillas, Juan Carlos Sánchez-Salgado, Emanuel Hernández-Núñez, Durcy Ruiz-Ciau
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Scientia Pharmaceutica
Subjects:
acute oral toxicity
flavonoids
hesperidin
naringenin
28–day oral toxicity
Online Access:https://www.mdpi.com/2218-0532/90/2/28

Internet

https://www.mdpi.com/2218-0532/90/2/28

Similar Items